Oxford BioMedica wins AMSCI funding

It was great to see so many members at our first autumn Biomedical Catalyst update meeting in Oxford. It was great to be able to discuss how the changes to the guidance will impact applications this time around. I’m looking forward to our next meeting in Nottingham on Tuesday evening which is really timely – as we are only a few weeks away from the deadline of 2 October for the current fourth round of Biomedical Catalyst funding.

While I was in Oxford I spoke with PharmaTelevision where I chatted with Fintan Walton about the BIA and what we do for the sector. I also highlighted some of our successes over recent years including the Biomedical Catalyst, R&D Tax Credits and the Patent Box and the need for a policy solution to address antimicrobial resistance following the publication of the government’s strategy.

Our UK Bioscience Forum programme is looking fantastic and I look forward to presenting the state of the sector report we are preparing with EY. The Bioscience Got Talent company showcase will focus on recent Biomedical Catalyst winners. This will provide members with a great opportunity to learn from companies that have already been successful in obtaining money ahead of the fifth round of the scheme.

I am delighted that the UK Bioscience Forum is now CPD-certified. CPD certification now enables bioscience professionals to use their attendance at the event as part of their ongoing professional development and training programme. Just one day provides over seven hours of CPD so it is a time- and cost-efficient way to make sure you are up to date with the latest developments in the sector, while developing your own skills and network.

On Wednesday, I’m looking forward to discussing alternative funding models at Bionow’s Biocap conference in Manchester. Its an early opportunity for the sector to suggest policy ideas for our life science manifesto so I look forward to meeting delegates there and discussing what issues we can best focus on to accelerate the development of companies in our sector.

Finally, I was pleased to see that Oxford BioMedica has received £7.72 million in grant and loan funding from the Advanced Manufacturing Supply Chain Initiative. Oxford BioMedica will lead a consortium of the Heart of England NHS Foundation, Cranfield University, Cell Therapy Catapult and Biotec Services International. The funding will support the development of a centre of excellence in advanced therapy medicinal products supply chains in the UK with a focus on gene-based therapies.